Ara-290 10mg

Comprehensive Guide to Ara-290 10mg (Cibinetide): Innate Repair Receptor Agonist Structure, Neuropathic Research Standards, and Analytical Purity

Welcome to Suzhou Lanhai Peptide, your trusted global source for advanced synthetic peptides, amino acid derivatives, and specialized laboratory storage solutions. In modern neuroprotection research, small-fiber neuropathy studies, and advanced pharmaceutical synthesis, investigating targeted non-erythropoietic peptide analogs requires absolute precision, verifiable purity, and strict compliance with research standards. When exploring innate repair receptor (IRR) activation, tissue protective signaling, and anti-inflammatory pathways, utilizing high-purity Ara-290 10mg (Cibinetide) is vital for achieving reproducible scientific outcomes.

This comprehensive guide explores the structural sequence, biochemical properties, analytical verification standards, and proper laboratory storage protocols for Ara-290 10mg. By examining real-world industry benchmarks and analytical chemistry standards, we outline why optimized sourcing and handling are fundamental to advanced neurological and metabolic research.

1. Understanding Ara-290 (Cibinetide): Structure, Mechanism, and Research Scope

Ara-290 (also known as Cibinetide) is a synthetic 11-amino acid peptide derived from the tertiary structure of erythropoietin (EPO), specifically engineered with the sequence pHGFLCCPGTC (often formulated with pyroglutamate or specific structural modifications depending on synthesis). Crucially, Ara-290 is designed to retain tissue-protective and anti-inflammatory properties while completely lacking erythropoietic activity (i.e., it does not stimulate red blood cell production).

The Mechanism of Action in Biomedical Research

In contemporary biochemical and pharmacological investigations, Ara-290 is examined for several key cellular pathways:

• Innate Repair Receptor (IRR) Activation: Ara-290 selectively binds to and activates the heterodimeric Innate Repair Receptor, composed of the erythropoietin receptor (EPOR) and the common beta receptor ($\beta cR$ / CD131). This activation occurs independently of the classical homodimeric EPO receptor involved in erythropoiesis.

• Reduction of Neuroinflammation and Cytokine Modulation: Research demonstrates that IRR activation inhibits nuclear factor kappa B (NF-$\kappa$B) signaling pathways, resulting in a marked down-regulation of pro-inflammatory cytokines (such as TNF-$\alpha$, IL-1$\beta$, and IL-6) in damaged neural and somatic tissues.

• Neuropathic Pain and Small-Fiber Regeneration Studies: In vitro and animal model research evaluates its efficacy in mitigating neuropathic pain, promoting small nerve fiber density restoration, and protecting tissues against metabolic and ischemic stress (such as in diabetic neuropathy models).

2. Analytical Verification and High-Purity Synthesis Standards

For institutional buyers, academic researchers, and biotechnology procurement managers, batch verification is paramount. Specialized disulfide-bonded peptides containing multiple cysteine residues require rigorous solid-phase peptide synthesis (SPPS), controlled oxidation/cyclization protocols, and HPLC purification to ensure correct disulfide bridge formation and structural fidelity.

High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS)

Every batch of Ara-290 10mg distributed by Suzhou Lanhai Peptide undergoes rigorous verification via HPLC and MS to guarantee purity levels exceeding 98% to 99%+, ensuring minimal uncyclized linear precursors, dimers, or synthesis impurities.

Technical Specification Comparison

3. Laboratory Handling, Reconstitution, and Storage Protocols

Synthetic peptides like Ara-290 are supplied as stabilized, vacuum-freeze-dried (lyophilized) powders to maximize shelf-life stability. Proper laboratory handling is essential to preserve peptide integrity upon reconstitution.

Reconstitution Best Practices

• Solvent Selection: Reconstitute lyophilized Ara-290 10mg using sterile bacteriostatic water for injection or analytical buffer solutions in a clean laminar flow hood.

• Avoiding Shear Stress: Introduce solvents gently down the inside wall of the vial rather than forcefully spraying liquid directly onto the lyophilized cake to prevent peptide bond shearing or disulfide bond disruption.

Cold-Chain Storage Guidelines

• Dry Powder Storage: Store sealed vials of lyophilized Ara-290 at $-20^\circ C$ desiccated away from light and moisture.

• Reconstituted Storage: Once reconstituted, solutions should be kept between $2^\circ C$ and $8^\circ C$ protected from light and utilized within short-term experimental windows to prevent enzymatic degradation or oxidation.

4. Mandatory Research Disclaimer and Compliance

• For Laboratory and Research Use Only: All peptide products offered by Suzhou Lanhai Peptide, including Ara-290 10mg, are strictly intended for in vitro laboratory research, analytical testing, and scientific study. They are not approved for human consumption, clinical trials on humans, veterinary use, or therapeutic self-administration.

5. Frequently Asked Questions (FAQs)

1. What is the structural relationship between Ara-290 and erythropoietin (EPO)?

Ara-290 is a synthetic 11-amino acid peptide fragment derived from EPO that retains tissue-protective signaling through the Innate Repair Receptor (IRR) while lacking erythropoietic (red blood cell-stimulating) activity.

2. What purity level does Suzhou Lanhai Peptide guarantee for Ara-290 10mg?

Every batch of Ara-290 10mg is backed by analytical documentation confirming an HPLC purity rating of 98% to 99% or higher.

3. How should lyophilized Ara-290 10mg be stored prior to reconstitution?

Lyophilized powder vials should be stored in a sealed, dry container at $-20^\circ C$ protected from light to maintain structural stability.

4. Are Certificates of Analysis (COAs) provided with orders?

Yes. Every order includes or provides access to batch-specific HPLC and Mass Spectrometry reports to verify purity and molecular weight for institutional compliance.

5. Can Ara-290 be used in human clinical applications?

No. All products sold by Suzhou Lanhai Peptide are restricted strictly to laboratory research and development use only and are prohibited from human or clinical application.